Jeito II is a Paris-based venture capital fund managed by Jeito Capital. €1.0bn reported at final close (source published April 2026).
Invest in clinical-stage biopharma companies with breakthrough therapies for severe diseases, committing capital at each value inflection point (15 to 20 companies).
Amounts come from the linked public source. A first close is not the final fund size, and a reported close does not confirm that the fund is investing now. Headquarters describe where the manager is based, not where it invests.